Description

1. Product Overview: Cenomate 12.5® is an antiepileptic formulation containing Cenobamate, designed for the treatment of partial-onset seizures in adult patients with epilepsy.
2. Composition: Cenobamate INN 12.5 mg | Dosage Form: Tablet
3. Pharmacological Class: Antiepileptic / Anticonvulsant
4. Mechanism of Action: Cenobamate acts by modulating voltage-gated sodium channels and enhancing inhibitory GABAergic activity, thereby stabilizing neuronal excitability and reducing seizure occurrence.
5. Indications: Partial-onset seizures in adults | Adjunct or monotherapy in epilepsy management
6. Dosage & Administration: As directed by physician only | Oral use | Dose must be gradually titrated to reduce risk of adverse effects
7. Clinical Benefits: Reduces seizure frequency | Improves seizure control | Enhances neurological stability | May improve quality of life in epilepsy patients
8. Contraindications: Hypersensitivity to Cenobamate or any component of the formulation
9. Precautions: Risk of serious skin reactions (rare) | May cause dizziness or somnolence | Gradual dose titration required | Do not discontinue abruptly
10. Drug Interactions: May interact with other antiepileptic drugs and CNS depressants | Can affect metabolism of certain medications via enzyme induction/inhibition
11. Special Populations: Not recommended during pregnancy unless clearly needed | Use in elderly and hepatic/renal impairment under medical supervision
12. Adverse Effects: Drowsiness | Dizziness | Fatigue | Headache | Possible serious skin reactions (rare)
13. Storage Conditions: Store below 30°C | Protect from light and moisture | Keep out of reach of children
14. Packaging: Tablet blister pack
15. Manufacturer: Everest Pharmaceutical Ltd.